These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16857665)

  • 21. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
    Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
    J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.
    Dong M; Miller LJ
    Peptides; 2013 Aug; 46():143-9. PubMed ID: 23770253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Receptor fragment approach to the binding between CCK8 peptide and cholecystokinin receptors: a fluorescence study on type B receptor fragment CCK(B)-R (352-379).
    De Luca S; Sanseverino M; Zocchi I; Pedone C; Morelli G; Ragone R
    Biopolymers; 2005 Mar; 77(4):205-11. PubMed ID: 15666329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.
    Kennedy K; Gigoux V; Escrieut C; Maigret B; Martinez J; Moroder L; Fréhel D; Gully D; Vaysse N; Fourmy D
    J Biol Chem; 1997 Jan; 272(5):2920-6. PubMed ID: 9006937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationships of FMRF-NH2 peptides demonstrate A role for the conserved C terminus and unique N-terminal extension in modulating cardiac contractility.
    Maynard BF; Bass C; Katanski C; Thakur K; Manoogian B; Leander M; Nichols R
    PLoS One; 2013; 8(9):e75502. PubMed ID: 24069424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.
    Ding XQ; Dolu V; Hadac EM; Holicky EL; Pinon DI; Lybrand TP; Miller LJ
    J Biol Chem; 2001 Feb; 276(6):4236-44. PubMed ID: 11050076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor.
    Ding XQ; Pinon DI; Furse KE; Lybrand TP; Miller LJ
    Mol Pharmacol; 2002 May; 61(5):1041-52. PubMed ID: 11961122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in partial agonist action at cholecystokinin receptors of mouse and rat are dependent on parameters extrinsic to receptor structure: molecular cloning, expression and functional characterization of the mouse type A cholecystokinin receptor.
    Ghanekar D; Hadac EM; Holicky EL; Miller LJ
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1206-12. PubMed ID: 9316827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones.
    Stone SR; Giragossian C; Mierke DF; Jackson GE
    Peptides; 2007 Nov; 28(11):2211-22. PubMed ID: 17950490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of activation of a G protein-coupled receptor, the human cholecystokinin-2 receptor.
    Marco E; Foucaud M; Langer I; Escrieut C; Tikhonova IG; Fourmy D
    J Biol Chem; 2007 Sep; 282(39):28779-28790. PubMed ID: 17599907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.
    Hadac EM; Dawson ES; Darrow JW; Sugg EE; Lybrand TP; Miller LJ
    J Med Chem; 2006 Feb; 49(3):850-63. PubMed ID: 16451051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spatial approximation between two residues in the mid-region of secretin and the amino terminus of its receptor. Incorporation of seven sets of such constraints into a three-dimensional model of the agonist-bound secretin receptor.
    Dong M; Li Z; Zang M; Pinon DI; Lybrand TP; Miller LJ
    J Biol Chem; 2003 Nov; 278(48):48300-12. PubMed ID: 14500709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor.
    Harikumar KG; Puri V; Singh RD; Hanada K; Pagano RE; Miller LJ
    J Biol Chem; 2005 Jan; 280(3):2176-85. PubMed ID: 15537636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
    Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of segment 32-47 of cholecystokinin receptor type A in CCK8 binding: synthesis, nuclear magnetic resonance, circular dichroism and fluorescence studies.
    De Luca S; Ragone R; Bracco C; Digilio G; Tesauro D; Saviano M; Pedone C; Morelli G
    J Pept Sci; 2003 Mar; 9(3):156-69. PubMed ID: 12675498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
    Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP
    Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequence variation outside the "active" region of dog and rabbit cholecystokinin-58 results in bioactivity differences.
    Reeve JR; Liddle RA; Shively JE; Lee TD; Keire DA; Chew P; Vigna SR
    Pancreas; 2006 Apr; 32(3):306-13. PubMed ID: 16628087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorescence studies on the binding between 1-47 fragment of cholecystokinin receptor CCK(A)-R(1-47) and nonsulfated cholecystokinin octapeptide CCK8.
    Ragone R; De Luca S; Tesauro D; Pedone C; Morelli G
    Biopolymers; 2000-2001; 56(1):47-53. PubMed ID: 11582577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor.
    Archer-Lahlou E; Tikhonova I; Escrieut C; Dufresne M; Seva C; Pradayrol L; Moroder L; Maigret B; Fourmy D
    J Med Chem; 2005 Jan; 48(1):180-91. PubMed ID: 15634012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.